Access

Letter

Nature Medicine 13, 1102 - 1107 (2007)
Published online: 2 September 2007 | Corrected online: 17 September 2007 | doi:10.1038/nm1632



There is a Corrigendum (October 2007) associated with this Letter.

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Sandeep T Patil1,13, Lu Zhang1, Ferenc Martenyi2, Stephen L Lowe3, Kimberley A Jackson4, Boris V Andreev5, Alla S Avedisova6, Leonid M Bardenstein7, Issak Y Gurovich8, Margarita A Morozova9, Sergey N Mosolov8, Nikolai G Neznanov10, Alexander M Reznik11, Anatoly B Smulevich9, Vladimir A Tochilov12, Bryan G Johnson1, James A Monn1 & Darryle D Schoepp1,13

Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathological features of disrupted neuronal excitability and plasticity within limbic structures of the brain. These pathological features manifest behaviorally as positive symptoms (including hallucinations, delusions and thought disorder), negative symptoms (such as social withdrawal, apathy and emotional blunting) and other psychopathological symptoms (such as psychomotor retardation, lack of insight, poor attention and impulse control)1. Altered glutamate neurotransmission has for decades been linked to schizophrenia, but all commonly prescribed antipsychotics act on dopamine receptors2. LY404039 is a selective agonist for metabotropic glutamate 2/3 (mGlu2/3) receptors3 and has shown antipsychotic potential in animal studies. With data from rodents, we provide new evidence that mGlu2/3 receptor agonists work by a distinct mechanism different from that of olanzapine. To clinically test this mechanism, an oral prodrug of LY404039 (LY2140023) was evaluated in schizophrenic patients with olanzapine as an active control in a randomized, three-armed, double-blind, placebo-controlled study. Treatment with LY2140023, like treatment with olanzapine, was safe and well-tolerated; treated patients showed statistically significant improvements in both positive and negative symptoms of schizophrenia compared to placebo (P < 0.001 at week 4). Notably, patients treated with LY2140023 did not differ from placebo-treated patients with respect to prolactin elevation, extrapyramidal symptoms or weight gain. These data suggest that mGlu2/3 receptor agonists have antipsychotic properties and may provide a new alternative for the treatment of schizophrenia.